D. Rozema

发表

Effects of side chain configuration and backbone spacing on the gene delivery properties of lysine-derived cationic polymers.

S. Gellman, Sarah E Eldred, Margaret R Pancost, 2005, Bioconjugate chemistry.

siRNA delivery technologies for mammalian systems

David L. Lewis, David B. Rozema, D. Lewis, 2003 .

Artificial chaperones-protein refolding via sequential use of detergent and cyclodextrin

S. Gellman, D. Rozema, 1995 .

Artificial chaperone-assisted refolding of denatured-reduced lysozyme: modulation of the competition between renaturation and aggregation.

S. Gellman, D. Rozema, 1996, Biochemistry.

Membrane activity and transfection ability of amphipathic polycations as a function of alkyl group size.

Darren H. Wakefield, J. Wolff, D. Rozema, 2005, Bioconjugate chemistry.

Endosomolysis by masking of a membrane-active agent (EMMA) for cytoplasmic release of macromolecules.

D. L. Lewis, J. Wolff, D. Rozema, 2003, Bioconjugate chemistry.

The CaaX Proteases, Afc1p and Rce1p, Have Overlapping but Distinct Substrate Specificities

J. Rine, C. Poulter, D. Rozema, 2000, Molecular and Cellular Biology.

Yeast protein farnesyltransferase. Site-directed mutagenesis of conserved residues in the beta-subunit.

C. Poulter, D. Rozema, J. Dolence, 1997, Biochemistry.

Biologically active maleamic acid derivatives with labile amide bonds

Darren H. Wakefield, J. Hagstrom, J. Wolff, 2003 .

Hepatocyte targeting of nucleic acid complexes and liposomes by a T7 phage p17 peptide.

Darren H. Wakefield, D. Lewis, J. Wolff, 2006, Molecular Pharmaceutics.

Yeast protein farnesyltransferase. pKas of peptide substrates bound as zinc thiolates.

C. Poulter, D. Rozema, 1999, Biochemistry.

Artificial Chaperone-assisted Refolding of Citrate Synthase*

S. Gellman, D. Rozema, Peter E. Hanson, 1998, The Journal of Biological Chemistry.

Artificial Chaperone-assisted Refolding of Carbonic Anhydrase B

S. Gellman, D. Rozema, 1996, The Journal of Biological Chemistry.

The Chemistry of Oligonucleotide Delivery

D. Rozema, 2017 .

Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes

Darren H. Wakefield, Tom W. Reppen, D. Lewis, 2007, Proceedings of the National Academy of Sciences.

Phosphorylation-specific status of RNAi triggers in pharmacokinetic and biodistribution analyses

Darren H. Wakefield, S. Kanner, D. Lewis, 2016, Nucleic acids research.

Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection

Alan McLachlan, Darren H. Wakefield, Qili Chu, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo.

Darren H. Wakefield, D. Lewis, D. Rozema, 2012, Nucleic acid therapeutics.

Targeting Factor 12 (F12) with a Novel RNAi Delivery Platform As a Prophylactic Treatment for Hereditary Angioedema (HAE)

Darren H. Wakefield, S. Melquist, D. Lewis, 2016 .

HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma

Darren H. Wakefield, S. Kanner, D. Lewis, 2017, Molecular Cancer Therapeutics.

HIF 2 a-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma

Eld, S. Kanner, D. Lewis, 2017 .

Title : HIF 2 α targeted RNAi therapeutic inhibits clear cell renal cell carcinoma

Darren H. Wakefield, S. Kanner, D. Lewis, 2017 .

Breaking the bonds: non-viral vectors become chemically dynamic.

J. Wolff, D. Rozema, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Protease-triggered siRNA delivery vehicles.

Darren H. Wakefield, D. Lewis, J. Wolff, 2015, Journal of controlled release : official journal of the Controlled Release Society.

RNAi therapeutics for the treatment of chronic hepatitis B virus infection

Darren H. Wakefield, D. Lewis, P. Hadwiger, 2012 .